Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe
- Autori: De Luca, A; Dunn, D; Zazzi, M; Camacho, R; Torti, C; Fanti, I; Kaiser, R; Sönnerborg, A; Codoñer, F; Van Laethem, K; Vandamme, A; Bansi, L; Ghisetti, V; Van De Vijver, D; Asboe, D; Prosperi, M; Di Giambenedetto, S; Mancuso, S
- Anno di pubblicazione: 2013
- Tipologia: Articolo in rivista (Articolo in rivista)
- Parole Chiave: antiretroviral therapy; drug resistance; epidemiology; genotyping; HIV-1; Adult; CD4 Lymphocyte Count; Databases, Factual; Europe; Evolution, Molecular; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sexual Behavior; pol Gene Products, Human Immunodeficiency Virus; Drug Resistance, Multiple, Viral; Infectious Diseases; Immunology and Allergy
- OA Link: http://hdl.handle.net/10447/215779
Abstract
HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis. © 2013 The Author.